Phase 1b Dose Escalation and Dose Expansion Trial of DV281 in Combination With an Approved Anti-PD-1 Inhibitor in Subjects With Advanced Non-Small Cell Lung Cancer
Latest Information Update: 05 Nov 2021
At a glance
- Drugs DV 281 (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Dynavax Technologies
- 09 Jun 2021 Results published in the Clinical Cancer Research
- 15 Jun 2020 Status changed from active, no longer recruiting to completed.
- 10 Jun 2019 Status changed from recruiting to active, no longer recruiting.